August 03, 2016
The global biomarkers market is expected to reach over $78.2 billion by 2024, according to a new report by Grand View Research, Inc.
The reports key finding state that
• the safety biomarkers segment held the largest share of over 40% in 2015
• the validation biomarkers segment is determined as one of the fastest growing segments
• the drug discovery segment dominated the application segment in 2015
• the cardiovascular segment is expected to be the fastest growing segment with a CAGR of over 14.0%
• North America held the largest regional share of around 39% in 2015
• Asia Pacific is anticipated to be the fastest growing biomarker market owing to the factors, such as the developing economic conditions, a large base of the target population, and a favorable regulatory scenario for clinical trials.
http://www.grandviewresearch.com/industry-analysis/biomarkers-industry
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.